INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO Inc. regarding allegations of securities fraud and unlawful business practices following a significant drop in stock price due to FDA clinical holds on its gene therapies [1]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether REGENXBIO and certain officers/directors engaged in securities fraud [1]. - Investors who purchased or acquired REGENXBIO securities during the Class Period have until April 14, 2026, to request appointment as Lead Plaintiff [1]. Group 2: FDA Clinical Holds - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant [1]. - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [1]. Group 3: Stock Price Impact - Following the FDA announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share on January 28, 2026 [1].